Daily aspirin use in healthy older adults increases the risk of serious bleeding while being taken, but this increased risk does not continue after stopping aspirin; bleeding rates after stopping are...
Mechanism
Synthesis from 1 study
Aspirin temporarily stops platelets from clumping and weakens the stomach’s natural defense, which causes more bleeding while you take it. Once you stop, your body replaces the affected cells and restores normal function, so bleeding risk goes back to normal — no lasting damage occurs.
Most probable mechanism
Aspirin blocks a key enzyme in platelets and the stomach lining, which reduces clotting and weakens the stomach's protective barrier. While taking aspirin, this causes more bleeding. Once aspirin is stopped, the body quickly restores normal enzyme activity in both platelets and the stomach, so bleeding risk returns to normal.
Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) in platelets, preventing the production of thromboxane A2, a molecule that promotes platelet aggregation and blood clot formation.
Reduced thromboxane A2 leads to decreased platelet activation and impaired clot formation, increasing susceptibility to bleeding during vascular injury.
Aspirin also inhibits COX-1 in gastric epithelial cells, suppressing synthesis of cytoprotective prostaglandins (PGE2 and PGI2) that maintain mucus secretion, bicarbonate neutralization, and mucosal blood flow.
Loss of prostaglandin-mediated protection makes the gastric lining vulnerable to acid and enzymatic damage, leading to erosion and clinically significant bleeding.
Upon discontinuation of aspirin, newly generated platelets with functional COX-1 enter circulation, restoring thromboxane A2 production and normal platelet function.
Simultaneously, COX-1 activity recovers in gastric mucosal cells, restoring prostaglandin synthesis and re-establishing mucosal defense mechanisms.
Restoration of both platelet aggregation capacity and gastric mucosal integrity returns bleeding risk to baseline levels within weeks after stopping aspirin.
Evidence from Studies
Supporting (1)
Community contributions welcome
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.